title: Protocol of GLUcose COntrol Safety and Efficacy in type 2 DIabetes, a NETwork meta-analysis: GLUCOSE DINET protocol-Rational and design.
abstract: The aim of this study was to propose a ranking of the currently available antidiabetic drugs, regarding vascular clinical outcomes, in patients with type 2 diabetes, through a network meta-analysis approach. Randomized clinical trials, regardless of the blinding design, testing contemporary antidiabetic drugs, and considering clinically relevant outcomes in patients with type 2 diabetes mellitus will be included. The primary outcomes of this analysis will be overall mortality, cardiovascular mortality, and major cardiovascular events. Diabetic microangiopathy will be a secondary outcome. Adverse events, hypoglycemia, weight evolution, bariatric surgery, and discontinuation of the treatment will also be recorded. Each drug will be analyzed according to its therapeutic class: biguanide, alpha-glucosidase inhibitors, sulfonylureas, glitazones, glinides, insulin, DPP-4 inhibitors, GLP-1 analogs, and gliflozins. The treatment effect of each drug class will be compared using pairwise meta-analysis and a Bayesian random model network meta-analysis. Sensitivity analyses will be conducted according to the quality of the studies and the glycemic control. The report will follow the PRISMA checklist for network meta-analysis. Results of the search strategy and of the study selection will be presented in a PRISMA compliant flowchart. The treatment effects will be summarized with odds ratio (OR) estimates and their 95% credible intervals. A ranking of the drugs will be proposed. Our network meta-analysis should allow a clinically relevant ranking of the contemporary antidiabetic drugs.
authors.affiliation: Hospices Civils de Lyon, Service de Pharmacologie Clinique et Essais Thérapeutiques, BP8071, 69376, Lyon, France.|Université de Lyon, Université Lyon 1, F-69000, Lyon, France.|Hospices Civils de Lyon, Hôpital Louis Pradel, Fédération d'endocrinologie, maladies métaboliques, diabète et nutrition, 69500, Bron, France.
authors.forename: Guillaume
authors.identifier: http://orcid.org/0000-0002-5237-2581
authors.initials: G
authors.lastname: Grenet
authors.affiliation: Centre d'Investigation Clinique, INSERM CIC 1407/UMR 5558 CNRS, 69500, Bron, France.
authors.forename: Audrey
authors.initials: A
authors.lastname: Lajoinie
authors.affiliation: Université de Lyon, Université Lyon 1, F-69000, Lyon, France.
authors.forename: Shams
authors.initials: S
authors.lastname: Ribault
authors.affiliation: Université de Lyon, Université Lyon 1, F-69000, Lyon, France.
authors.forename: Gia Bao
authors.initials: GB
authors.lastname: Nguyen
authors.affiliation: Université de Lyon, Université Lyon 1, F-69000, Lyon, France.
authors.forename: Thomas
authors.initials: T
authors.lastname: Linet
authors.affiliation: Université de Lyon, Université Lyon 1, F-69000, Lyon, France.
authors.forename: Augustin
authors.initials: A
authors.lastname: Metge
authors.affiliation: Hospices Civils de Lyon, Service de Pharmacologie Clinique et Essais Thérapeutiques, BP8071, 69376, Lyon, France.|Université de Lyon, Université Lyon 1, F-69000, Lyon, France.|Centre d'Investigation Clinique, INSERM CIC 1407/UMR 5558 CNRS, 69500, Bron, France.|Laboratoire de Biométrie et Biologie Evolutive, Université Lyon 1, CNRS, UMR5558, F-69372, Lyon Cedex 08, France.
authors.forename: Catherine
authors.initials: C
authors.lastname: Cornu
authors.affiliation: Laboratoire de Biométrie et Biologie Evolutive, Université Lyon 1, CNRS, UMR5558, F-69372, Lyon Cedex 08, France.
authors.forename: Michel
authors.initials: M
authors.lastname: Cucherat
authors.affiliation: Hospices Civils de Lyon, Hôpital Louis Pradel, Fédération d'endocrinologie, maladies métaboliques, diabète et nutrition, 69500, Bron, France.|INSERM U1060, Université Lyon 1, 69622, Villeurbanne, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Moulin
authors.affiliation: Hospices Civils de Lyon, Service de Pharmacologie Clinique et Essais Thérapeutiques, BP8071, 69376, Lyon, France.|Université de Lyon, Université Lyon 1, F-69000, Lyon, France.|Centre d'Investigation Clinique, INSERM CIC 1407/UMR 5558 CNRS, 69500, Bron, France.|Laboratoire de Biométrie et Biologie Evolutive, Université Lyon 1, CNRS, UMR5558, F-69372, Lyon Cedex 08, France.
authors.forename: François
authors.initials: F
authors.lastname: Gueyffier
mesh_terms: D006801:Humans; D001786:Blood Glucose / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D005947:Glucose / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D000071076:Network Meta-Analysis as Topic
chemical_list: D001786:Blood Glucose; D005947:Glucose; D007004:Hypoglycemic Agents
keywords: cardiovascular diseases; glucose-lowering drugs; network meta-analysis; type 2 diabetes